Home / Treatments / Cyberknife Radiosurgery
Cyberknife Radiosurgery denials: what the review data shows
Independent reviewers have decided 13 published cases where an insurer denied Cyberknife Radiosurgery — and they overturned the insurer 46.2% of the time. A denial for Cyberknife Radiosurgery is a starting position, not a final answer.
Published decisions
13
2001–2026
Overturned
46.2%
6 denials reversed
Conditions behind cyberknife radiosurgery denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Prostate Cancer | 5 | 40% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 8 | 50% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 5 | 40% |
Typical time to a decision
7 days
Most land between 3 and 13 days
Handled as urgent
84.6%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
The patient is a 59-year-old male who presented with stage IV non-small cell lung cancer in August 2004. He received external beam radiation therapy for metastatic disease to his spine. This was followed by Cyberknife radiosurgery and then surgical resection. This was then followed by systemic chemotherapy for progressive disease. Recently, the patient was diagnosed with a single right parietal brain metastatic lesion. The options discussed were Cyberknife radiosurgery alone versus whole brain radiation therapy with Cyberknife boost. The patient wishes to proceed with Cyberknife radiosurgery without whole brain radiation. The Health Plan has denied authorization for the requested procedure on the basis that it is not medically necessary in this clinical setting.This patient with stage IV lung cancer has been treated aggressively to date, especially for the spinal metastatic disease.
A 49-year-old male enrollee has requested authorization and coverage for radiosurgery via CyberKnife for treatment of the enrollee’s acoustic neuroma. Findings: The physician reviewer found that stereotactic radiosurgery has become a well-established treatment modality in the management of selected patients with acoustic neuromas. According to German, et al., among neurotologists, 42% perform stereotactic radiosurgery (approximately 58% of those use Gamma Knife, and 44% use CyberKnife) and 37% percent of patients seen by neurotologists receive radiation. Results are better than with those obtained using whole-brain radiotherapy and comparable to the best selected surgery-radiation series. However, review of the relevant peer-reviewed evidence does not reveal adequate data that CyberKnife is superior to conventional radiosurgery in this setting.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
A 57-year-old female enrollee has requested CyberKnife radiosurgery for the treatment of her acoustic neuroma. Findings: The physician reviewer found that the three major treatment options for acoustic neuromas are observation, surgery, and radiation therapy. Observation is usually reserved for patients whose symptoms and/or tumor size are stable or progressing only slowly. Stereotactic radiosurgery (SRS) is a technique that utilizes multiple convergent beams to deliver a single high dose of radiation to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures. This can be accomplished with either the gamma knife or a linear accelerator. Radiosurgery is a viable treatment option for selected patients with smaller tumors (less than 3 cm) or for enlarging tumors in patients who are not candidates for surgery.
A 63-year-old male enrollee has requested CyberKnife radiosurgery for the treatment of his unresectable hilar cholangiocarcinoma. Findings: Three physician reviewers found that locally advanced, metastatic gallbladder cancer has a poor prognosis. Radiation is used primarily for palliation of symptoms from local progression, such as biliary obstruction, bowel obstruction and splanchnic nerve pain. Decades of literature indicates that radiotherapy with unresectable gallbladder cancer is medically indicated. Chemotherapy also is used for palliation, and the standard treatment in patients with reasonably good performance status is to offer both chemotherapy and radiation. With newer technology, newer tools are available to deliver the radiation.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Cyberknife Radiosurgerywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.